Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

medicines value

This page shows the latest medicines value news and features for those working in and with pharma, biotech and healthcare.

Duchenne UK and pharma partner pilot data-sharing HTA approach

Duchenne UK and pharma partner pilot data-sharing HTA approach

reach regulatory approval; how we get governments and health services to pay for these medicines, ”said the charity. ... The hope is that the model could also be used for other rare diseases and provide greater certainty over the value that new

Latest news

  • NICE to look again at Pfizer’s Besponsa after appeal NICE to look again at Pfizer’s Besponsa after appeal

    assessment. It reacted furiously at the time of the rejection, describing the decision as “another example of how NICE is not appropriately assessing the value of modern cancer medicines, leaving patients

  • What value for innovation in an era dominated by affordability? What value for innovation in an era dominated by affordability?

    What value for innovation in an era dominated by affordability? Pharma can collaborate but must be clear about its motives. ... There is nonetheless an urgent need to reframe the debate around medical innovation and support healthcare systems to improve

  • Europe’s cancer drug regulation is ‘broken’, claims study Europe’s cancer drug regulation is ‘broken’, claims study

    A new study has suggested that 57% of cancer drug uses approved by the European Medicines Agency ( EMA) between 2009 and 2013 do not provide survival or quality-of-life benefits. ... The European Federation of Pharmaceutical Industries and Associations (

  • NICE: We're the institute of 'yes' NICE: We're the institute of 'yes'

    However, he questioned the industry's current approach to setting out the value offered by new medicines. ... commercial discussion with NICE, NHS England and companies, and use of more flexible criteria to assess value.

  • NICE set to reject Pfizer's leukaemia drug Besponsa NICE set to reject Pfizer's leukaemia drug Besponsa

    The firm added that assumptions made during the process were ‘inconsistent’with previous appraisals of other medicines in the disease area. ... David Montogomery, oncology medical director at Pfizer UK, said: “[This] frustrating decision for

More from news
Approximately 2 fully matching, plus 122 partially matching documents found.

Latest Intelligence

  • Working with our healthcare system more closely is vital Working with our healthcare system more closely is vital

    The new scheme needs to be balanced to ensure that patients get the new medicines they need; deliver value for money for the NHS; and enable a thriving UK pharmaceutical sector ... that can continue to innovate in medicines and create jobs and value to

  • Adding value in emerging markets Adding value in emerging markets

    Branded generics offer something of value. When you think of generic medicines, you think low cost, high volume, little differentiation. ... Well, there are a number of ways to add value to off-patent medicines.

  • Biosimilars: what the future looks like Biosimilars: what the future looks like

    itself. We must build on the experience gained over the years of development and identify new opportunities where these medicines can truly add value. ... This also marked the culmination of many years of commitment and people’s personal journeys to

  • Righting pharma’s reputational wrongs Righting pharma’s reputational wrongs

    People say we have a powerful story to tell about the value of our medicines but are poor at getting the message across. ... These relationships are incredibly important and play a vital role in the development and delivery of new medicines.

  • Can UK pharma rise to the post-Brexit challenge? Can UK pharma rise to the post-Brexit challenge?

    So, what do we know? The future of the European Medicines Agency (EMA). ... 5.Finally, the value of NICE Guidance in supporting the international use of medicines is very important indeed to the role of the UK in global pharmaceuticals.

More from intelligence
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest appointments

  • Sanofi appoints Dr Yong-Jun Liu as head of research Sanofi appoints Dr Yong-Jun Liu as head of research

    In his new role, Dr Liu will be responsible for all of the Paris-based pharmaceutical company's research and will be tasked with delivering innovative and high-value medicines.

  • ABPI Scotland appoints Sandra Auld as director ABPI Scotland appoints Sandra Auld as director

    the access to and use of new and innovative medicines for Scottish patients. “ ... The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • How to measure health behaviour change programmes

    The value outcome of medicines is still largely measured against healthcare systems or general societal outcomes. ... But the ways in which we measure patient benefits and value needs to be equally creative.

  • How will the NHS’s new medicines savings drive affect pharma?

    value medicines that can be easily bought over-the-counter, such as antihistamines and sun cream. ... In conclusion, the need for pharma to prove the value of its products has never been greater.

  • Packer Forbes collaborates with NHS Expert to strengthen growing team

    With today’ s emphasis on economic as well as clinical value, it recognises access barriers to medicines as a key challenge and works to uncover insightful understanding of the issues in

  • Value of Medicines

    Value of Medicines. By focusing on cost are we obscuring the true value of medicines? ... David Coleiro, Paula Lashley and John Grime take a look at how society values medicines, the role of health technology assessment (HTA) bodies like NICE, what value

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia